Pfizer’s rheumatoid arthritis drug shows treatment benefit in combination but not alone

Pfizer’s phase 3B/4 study evaluating its Xeljanz (tofacitinib citrate) drug, a treatment for moderate to severe rheumatoid arthritis (RA), met its primary endpoint in combination with methotrexate (MTX) against AbbVie’s adalimumab (Humira) but didn’t meet the primary endpoint on its own.

Filed under: Arthritis